114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.
38 citations
,
September 2006 in “Journal of Dermatological Science” This study evaluated the effect of 2% ketoconazole lotion for androgenetic alopecia, but the results regarding its effectiveness on clinical appearance remained unclear.
108 citations
,
March 2006 in “Archives of Dermatology” This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.
33 citations
,
December 2005 in “Archives of dermatology” This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.
75 citations
,
June 2005 in “Archives of Dermatology” In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.
74 citations
,
April 2005 in “Dermatologic Clinics” This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.
182 citations
,
October 2003 in “British Journal of Dermatology” These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.
190 citations
,
October 2002 in “The FASEB journal” In this study, androgen did not affect keratinocyte growth in coculture with androgenetic alopecia-derived dermal papilla cells, but did significantly suppress keratinocyte growth when androgen receptor was overexpressed in the papilla cells.
83 citations
,
December 2001 in “Journal of Investigative Dermatology” Minoxidil boosts hair growth by targeting adenosine and possibly sulfonylurea receptor 2B.
66 citations
,
January 2000 in “Hormone Research in Paediatrics” This study suggests that the paradoxical effects of androgens on hair growth are due to differential gene expression in hair follicles, possibly established during embryogenesis.
370 citations
,
September 1999 in “The New England Journal of Medicine” This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
131 citations
,
November 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that alopecia areata can be induced and serially transferred in C3H/HeJ mice using skin grafts, providing a useful model for studying the disease in humans.
227 citations
,
January 1998 in “Journal of Endocrinology” This study found that dermal papilla cells from balding scalp hair follicles have significantly higher levels of androgen receptors than those from non-balding follicles, supporting their in vivo androgen response.
20 citations
,
December 1997 in “Clinical Endocrinology” This article discusses the potential beneficial effect of spironolactone on androgenic alopecia but provides no new clinical findings.
101 citations
,
November 1992 in “Archives of Dermatology” In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.
124 citations
,
April 1992 in “Journal of Endocrinology/Journal of endocrinology” This study observed that cells from androgen-sensitive areas like the beard and scrotum showed higher androgen receptor levels compared to those from non-balding scalp areas, supporting the role of dermal papilla in follicle growth responses to androgens.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.
164 citations
,
November 1989 in “Clinical and Experimental Dermatology” This retrospective study found that juvenile alopecia areata is more severe and has a worse prognosis than maturity-onset alopecia areata.
109 citations
,
November 1987 in “Archives of dermatology” In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
63 citations
,
April 1985 in “Journal of the American Academy of Dermatology” This study observed that topical PUVA treatment led to excellent or good hair regrowth in 45.4% of patients with alopecia areata, though many experienced relapse after treatment stopped.
666 citations
,
September 1977 in “British Journal of Dermatology” This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.